BHVN

Biohaven Pharmaceutical Holding Co Ltd

A biopharmaceutical company developing experimental therapies for neurological, immune, and metabolic diseases. Founded in 2013 in New Haven, Connecticut, it won FDA approval for the migraine drug Nurtec ODT before Pfizer bought that franchise in 2022, leaving the rest of the pipeline to carry on as the current company. Its name blends "bio" with "haven" — a nod to its home city.